查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1821540

2025年全球癌症腫瘤分析市場報告

Cancer Tumor Profiling Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年癌症腫瘤分析市場將快速成長，到2029年將達到251.2億美元，複合年成長率為13.8%。預測期內的成長可歸因於免疫療法和免疫分析在癌症治療中的應用擴展、液態切片和非侵入性腫瘤分析方法的發展、單細胞測序在更詳細地表徵腫瘤方面的應用、癌症篩檢和早期檢測項目的擴展，以及對罕見癌症和罕見癌症亞型分析需求的不斷成長。預測期內的主要趨勢包括腫瘤分析融入常規臨床實踐、多體學方法的進展、人工智慧 (AI) 和機器學習在數據分析中的整合、個人化醫療和靶向標靶治療的開發，以及基因組分析和次世代定序儀(NGS) 技術的進步。

我們預測未來五年的成長率為13.8%，較先前的預測略有下降0.2個百分點。這一下降主要源自於美國與其他國家之間關稅的影響。徵收關稅可能會對美國的精準醫療構成重大挑戰，因為這會限制美國從加拿大和瑞典進口的多組體學分析服務和基於人工智慧 (AI) 的腫瘤分析軟體，從而可能危及個人化治療方案。由於互惠關稅以及貿易緊張局勢和限制措施加劇對全球經濟和貿易的負面影響，關稅的影響也可能更為廣泛。

全球癌症發生率的上升預計將推動癌症和腫瘤分析市場的未來成長。癌症是一種以體內某些細胞不受控制地生長為特徵的疾病，這些細胞可能轉移到身體的其他部位。隨著癌症病例的增加，對腫瘤分析的需求也將增加，因為它有助於醫生評估疾病的嚴重程度。例如，美國專業組織美國癌症協會報告稱，2024年美國將新增200萬例癌症病例，高於2023年的190萬例。因此，全球癌症發生率的上升正在刺激癌症和腫瘤分析市場的成長。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球癌症腫瘤分析：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球癌症腫瘤分析市場：成長率分析
  • 全球癌症腫瘤分析市場表現：規模與成長，2019-2024
  • 全球癌症腫瘤分析市場預測：規模與成長，2024-2029 年，2034 年
  • 全球癌症腫瘤分析：總潛在市場（TAM）

第6章 市場細分

  • 全球癌症腫瘤分析市場（按癌症類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 攝護腺癌
  • 黑色素瘤
  • 卵巢癌
  • 胃癌
  • 胰臟癌
  • 甲狀腺癌
  • 其他類型的癌症
  • 全球癌症腫瘤分析市場：依技術、績效與預測，2019-2024 年、2024-2029 年、2034 年
  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 免疫組織化學（IHC）
  • 原位雜合技術（ISH）
  • 微陣列
  • 其他技術
  • 全球癌症腫瘤分析市場（依流程類型、實際及預測），2019-2024 年、2024-2029 年、2034 年
  • 基因組學
  • 蛋白質體學
  • 表觀遺傳學
  • 代謝體學
  • 其他類型
  • 全球癌症腫瘤分析市場：依應用、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 個人化醫療
  • 診斷
  • 生物標記發現
  • 預後
  • 調查應用
  • 全球癌症腫瘤分析市場：依肺癌類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 非小細胞肺癌（NSCLC）
  • 小細胞肺癌（SCLC）
  • 全球癌症腫瘤分析市場：乳癌細分（依癌症類型）、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 荷爾蒙受體陽性
  • 三陰性乳癌
  • HER2陽性乳癌
  • 全球癌症腫瘤分析市場：細分：大腸直腸癌（按癌症類型），實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 大腸直腸癌
  • 直腸癌
  • 全球癌症腫瘤分析市場：前列腺癌類型細分、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 局部前列腺癌
  • 進行性前列腺癌
  • 全球癌症腫瘤分析市場：惡性黑色素瘤細分（按癌症類型）、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 皮膚黑色素瘤
  • 非皮膚黑色素瘤
  • 全球癌症腫瘤分析市場：依卵巢癌類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 上皮性卵巢癌
  • 非上皮性卵巢癌
  • 全球癌症腫瘤分析市場：依胃癌類型、表現及預測細分，2019-2024 年、2024-2029 年、2034 年
  • 胃腺癌
  • 胃腸道基質腫瘤（GIST）
  • 全球癌症腫瘤分析市場：依癌症類型（胰臟癌）細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 外分泌性胰臟癌
  • 神經內分泌腫瘤
  • 全球癌症腫瘤分析市場：甲狀腺癌細分（依癌症類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 甲狀腺乳突癌
  • 濾泡性甲狀腺癌
  • 甲狀腺髓樣癌
  • 全球癌症腫瘤分析市場：其他癌症類型細分（按癌症類型），實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 腎癌
  • 膀胱癌
  • 肝癌
  • 食道癌

第7章 區域和國家分析

  • 全球癌症腫瘤分析市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球癌症腫瘤分析市場：按國家、績效和預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 癌症腫瘤分析市場：競爭格局
  • 癌症腫瘤分析市場：公司簡介
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Caris Life Sciences Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Qiagen Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Ribomed Biotechnologies Inc.
  • HTG Molecular Diagnostics Inc.
  • NanoString Technologies Inc.
  • NeoGenomics Laboratories Inc.
  • Lucence Health Inc.
  • ACT Genomics Co. LTD
  • Strand Life Sciences
  • IMB Dx Inc.
  • Exact Sciences Corporation
  • Guardant Health
  • Foundation Medicine Inc.
  • Agilent Technologies Inc.
  • Myriad Genetics Inc.
  • Personal Genome Diagnostics Inc.
  • Tempus Labs Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年癌症腫瘤分析市場：提供新機會的國家
  • 2029年癌症腫瘤分析市場：細分領域帶來新機會
  • 2029年癌症腫瘤分析市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r21188u

Cancer tumor profiling is a laboratory testing method designed to analyze a sample of tumor tissue for specific genes, gene mutations, proteins, or other biomarkers. This comprehensive examination aids in treatment planning and provides valuable insights into the likelihood of cancer recurrence or metastasis.

The primary categories of cancer and tumor profiling encompass lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and various other cancer types. Diverse technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, are employed in this process. These technologies cover multiple facets, including genomics, proteomics, epigenetics, metabolomics, and more. Cancer and tumor profiling find applications in personalized medicine, diagnostics, biomarker discovery, prognostics, and research endeavors.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cancer tumor profiling market research report is one of a series of new reports from The Business Research Company that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer tumor profiling market size has grown rapidly in recent years. It will grow from $13 billion in 2024 to $14.97 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to increasing cancer incidence, growth in precision medicine initiatives and research collaborations, improved cancer diagnostics and early detection methods, availability of a wide range of targeted therapy options, and supportive regulatory frameworks for cancer profiling tests.

The cancer tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $25.12 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to expansion of immunotherapy and immunoprofiling in cancer treatment, development of liquid biopsy and non-invasive tumor profiling methods, adoption of single-cell sequencing for more detailed tumor characterization, expansion of cancer screening and early detection programs, and increasing demand for rare and orphan cancer subtype profiling. Major trends in the forecast period include integration of tumor profiling into routine clinical practice, advances in multi-omics approaches, integration of artificial intelligence (AI) and machine learning in data analysis, personalized medicine and targeted therapy development, and advances in genomics and next-generation sequencing (ngs) technologies.

The forecast of 13.8% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. precision medicine by restricting access to multi-omic profiling services and Artificial intelligence(AI)-based tumor analysis software imported from Canada and Sweden, potentially compromising personalized therapy selection. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of cancer worldwide is anticipated to drive the growth of the cancer and tumor profiling market in the future. Cancer is a disease characterized by the uncontrolled growth of certain cells in the body, which can spread to other areas. As the number of cancer cases increases, the demand for tumor profiling also rises, as it helps doctors assess the severity of the disease. For example, in 2024, the American Cancer Society, a US-based professional organization, reported that 2 million new cancer cases were diagnosed in the country, an increase from 1.9 million new cases in 2023. Consequently, the increasing incidence of cancer globally is fueling the growth of the cancer and tumor profiling market.

The increasing prevalence of stomach cancer is anticipated to be a key driver for the growth of the cancer and tumor profiling market. Stomach cancer involves the uncontrolled growth of malignant cells in the stomach lining, and cancer and tumor profiling play a crucial role in providing insights into the development of this disease. For example, gastrointestinal stromal tumors (GISTs), though distinct from stomach cancer, can occur in the stomach, and cancer and tumor profiling can help in understanding and treating such cases. As indicated by Cancer Research UK, the incidence of stomach cancer in the UK is expected to decline by 12% between 2023-2025 and 2038-2040. This decline, while positive, highlights the need for continued focus on stomach cancer research and tumor profiling to further address the disease. The growing prevalence of stomach cancer is thus contributing to the expansion of the cancer and tumor profiling market.

Increasing research and development activities are emerging as a significant trend in the cancer and tumor profiling market. Major companies in this sector are prioritizing research and development to meet consumer demands and strengthen their market position. For instance, QIAGEN N.V, a German company specializing in sample and assay technology, recently announced the Conformite Europeenne (CE)-marking and commercialization of the therascreen PIK3CA RGQ PCR Kit in Europe. This diagnostic assay is designed to identify breast cancer patients with PIK3CA mutations, providing crucial information for personalized treatment. The emphasis on research and development activities is a notable trend that is shaping the cancer and tumor profiling market.

In June 2023, Quest Diagnostics, a prominent US-based medical laboratory company, completed the acquisition of Haystack Oncology Inc. for a substantial sum of $450 million. The strategic move by Quest Diagnostics is aimed at broadening access to liquid biopsy technology and strengthening its position in the competitive field of cancer diagnostics. This acquisition is anticipated to augment Quest Diagnostics' research and development capabilities, thereby enhancing its ability to contribute to improved outcomes for cancer patients. Haystack Oncology Inc., based in the United States, is an early-stage oncology company specializing in the development of solid tumor testing technology.

In June 2023, Quest Diagnostics, a US-based medical laboratory firm, acquired Haystack Oncology Inc. for $450 million. This acquisition is intended to broaden access to liquid biopsy technology and enhance Quest Diagnostics' market share in cancer diagnostics by improving research and development capabilities. Haystack Oncology Inc. is a US-based early-stage oncology company focused on developing solid tumor testing technologies aimed at improving outcomes for cancer patients.

Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer and tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Tumor Profiling Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer tumor profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer tumor profiling ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer tumor profiling market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types
  • 2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies
  • 3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types
  • 4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications
  • Subsegments:
  • 1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)
  • 2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer
  • 3) By Colorectal Cancer: Colon Cancer; Rectal Cancer
  • 4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer
  • 5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma
  • 6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer
  • 7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)
  • 8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors
  • 9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer
  • 10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Caris Life Sciences; Thermo Fisher Scientific Inc.; Illumina Inc.; Qiagen; Ribomed Biotechnologies Inc.; HTG Molecular Diagnostics Inc.; NanoString Technologies Inc.; NeoGenomics Laboratories Inc.; Lucence Health Inc.; ACT Genomics Co. LTD; Strand Life Sciences; IMB Dx Inc.; Exact Sciences Corporation; Guardant Health; Foundation Medicine Inc.; Agilent Technologies Inc.; Myriad Genetics Inc.; Personal Genome Diagnostics Inc.; Tempus Labs Inc.; ArcherDX Inc.; Natera Inc.; Bio-Rad Laboratories Inc.; Genetron Health; NantHealth Inc.; Resolution Bioscience; Genomic Testing Cooperative; OncoDNA; Strata Oncology Inc.; Genuity Science; RareCyte Inc.; Inivata Limited; Cepheid
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Tumor Profiling Market Characteristics

3. Cancer Tumor Profiling Market Trends And Strategies

4. Cancer Tumor Profiling Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cancer Tumor Profiling Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cancer Tumor Profiling PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cancer Tumor Profiling Market Growth Rate Analysis
  • 5.4. Global Cancer Tumor Profiling Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cancer Tumor Profiling Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cancer Tumor Profiling Total Addressable Market (TAM)

6. Cancer Tumor Profiling Market Segmentation

  • 6.1. Global Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Ovarian Cancer
  • Stomach Cancer
  • Pancreatic Cancer
  • Thyroid Cancer
  • Other Cancer Types
  • 6.2. Global Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Microarray
  • Other Technologies
  • 6.3. Global Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Genomics
  • Proteomics
  • Epigenetics
  • Metabolomics
  • Other Types
  • 6.4. Global Cancer Tumor Profiling Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Personalized Medicine
  • Diagnostics
  • Biomarker Discovery
  • Prognostics
  • Research Applications
  • 6.5. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Lung Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)
  • 6.6. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Breast Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormone Receptor-Positive
  • Triple-Negative Breast Cancer
  • HER2-Positive Breast Cancer
  • 6.7. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Colorectal Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Colon Cancer
  • Rectal Cancer
  • 6.8. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Prostate Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Localized Prostate Cancer
  • Advanced Prostate Cancer
  • 6.9. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Melanoma, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cutaneous Melanoma
  • Non-Cutaneous Melanoma
  • 6.10. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Ovarian Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Epithelial Ovarian Cancer
  • Non-Epithelial Ovarian Cancer
  • 6.11. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Stomach Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gastric Adenocarcinoma
  • Gastrointestinal Stromal Tumors (GISTs)
  • 6.12. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Pancreatic Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Exocrine Pancreatic Cancer
  • Neuroendocrine Tumors
  • 6.13. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Thyroid Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Papillary Thyroid Cancer
  • Follicular Thyroid Cancer
  • Medullary Thyroid Cancer
  • 6.14. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Other Cancer Types, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Kidney Cancer
  • Bladder Cancer
  • Liver Cancer
  • Esophageal Cancer

7. Cancer Tumor Profiling Market Regional And Country Analysis

  • 7.1. Global Cancer Tumor Profiling Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cancer Tumor Profiling Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Tumor Profiling Market

  • 8.1. Asia-Pacific Cancer Tumor Profiling Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Tumor Profiling Market

  • 9.1. China Cancer Tumor Profiling Market Overview
  • 9.2. China Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Tumor Profiling Market

  • 10.1. India Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Tumor Profiling Market

  • 11.1. Japan Cancer Tumor Profiling Market Overview
  • 11.2. Japan Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Tumor Profiling Market

  • 12.1. Australia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Tumor Profiling Market

  • 13.1. Indonesia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Tumor Profiling Market

  • 14.1. South Korea Cancer Tumor Profiling Market Overview
  • 14.2. South Korea Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Tumor Profiling Market

  • 15.1. Western Europe Cancer Tumor Profiling Market Overview
  • 15.2. Western Europe Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Tumor Profiling Market

  • 16.1. UK Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Tumor Profiling Market

  • 17.1. Germany Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Tumor Profiling Market

  • 18.1. France Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Tumor Profiling Market

  • 19.1. Italy Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Tumor Profiling Market

  • 20.1. Spain Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Tumor Profiling Market

  • 21.1. Eastern Europe Cancer Tumor Profiling Market Overview
  • 21.2. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Tumor Profiling Market

  • 22.1. Russia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Tumor Profiling Market

  • 23.1. North America Cancer Tumor Profiling Market Overview
  • 23.2. North America Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Tumor Profiling Market

  • 24.1. USA Cancer Tumor Profiling Market Overview
  • 24.2. USA Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Tumor Profiling Market

  • 25.1. Canada Cancer Tumor Profiling Market Overview
  • 25.2. Canada Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Tumor Profiling Market

  • 26.1. South America Cancer Tumor Profiling Market Overview
  • 26.2. South America Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Tumor Profiling Market

  • 27.1. Brazil Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Tumor Profiling Market

  • 28.1. Middle East Cancer Tumor Profiling Market Overview
  • 28.2. Middle East Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Tumor Profiling Market

  • 29.1. Africa Cancer Tumor Profiling Market Overview
  • 29.2. Africa Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Tumor Profiling Market Competitive Landscape And Company Profiles

  • 30.1. Cancer Tumor Profiling Market Competitive Landscape
  • 30.2. Cancer Tumor Profiling Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Caris Life Sciences Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Qiagen Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Tumor Profiling Market Other Major And Innovative Companies

  • 31.1. Ribomed Biotechnologies Inc.
  • 31.2. HTG Molecular Diagnostics Inc.
  • 31.3. NanoString Technologies Inc.
  • 31.4. NeoGenomics Laboratories Inc.
  • 31.5. Lucence Health Inc.
  • 31.6. ACT Genomics Co. LTD
  • 31.7. Strand Life Sciences
  • 31.8. IMB Dx Inc.
  • 31.9. Exact Sciences Corporation
  • 31.10. Guardant Health
  • 31.11. Foundation Medicine Inc.
  • 31.12. Agilent Technologies Inc.
  • 31.13. Myriad Genetics Inc.
  • 31.14. Personal Genome Diagnostics Inc.
  • 31.15. Tempus Labs Inc.

32. Global Cancer Tumor Profiling Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Tumor Profiling Market

34. Recent Developments In The Cancer Tumor Profiling Market

35. Cancer Tumor Profiling Market High Potential Countries, Segments and Strategies

  • 35.1 Cancer Tumor Profiling Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Cancer Tumor Profiling Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Cancer Tumor Profiling Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer